Fierce Biotech reports that GE will team up with J&J to find new-presymptomatic biomarkers for Alzheimer's disease. The markers will be used to accelerate diagnosis and treatment. The two will try to use GE's Flutemetamol imaging agent to identify Alzheimer's very very early in disease progression. The tool may help J&J and its partner Pfizer select patients for treatment with new Alzheimer drug candidates, like their bapineuzumab.
Posted by Bruce Lehr December 3rd 2010.